<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>美药专利法观察 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-18T12:16:24+08:00</updated>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>多肽药产品的名分之争，Teva遏制仿制药诉讼受挫</title>
    <updated>2021-01-18T06:33:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/DSJd4a4-wFq5F2spYsLMoA</id>
    <link href="https://mp.weixin.qq.com/s/DSJd4a4-wFq5F2spYsLMoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药片不设“目标”！本所团队完胜获专利无效上诉判决</title>
    <updated>2021-01-11T03:54:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/znAGmJWnlYDrjc_EO2I7Bw</id>
    <link href="https://mp.weixin.qq.com/s/znAGmJWnlYDrjc_EO2I7Bw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国上诉判决: 等同侵权-权利要求中化学名取代商品名未构成专利范围变窄</title>
    <updated>2021-01-04T05:11:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/g6Z0OdN0Up6HJle5tulNlw</id>
    <link href="https://mp.weixin.qq.com/s/g6Z0OdN0Up6HJle5tulNlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年度美国重要相关专利案例回顾和进展</title>
    <updated>2020-12-28T01:18:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/QoMdvV3tbT7DgLEX12mnsw</id>
    <link href="https://mp.weixin.qq.com/s/QoMdvV3tbT7DgLEX12mnsw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国上诉判决: 制剂专利的几个常见词是什么意思？</title>
    <updated>2020-12-21T05:22:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-21:/s/DuGrr1-B1RjKc3P0GV36pQ</id>
    <link href="https://mp.weixin.qq.com/s/DuGrr1-B1RjKc3P0GV36pQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>No Standing – 原告的诉讼“站得住脚”吗？</title>
    <updated>2020-12-14T06:22:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/Wy5KPYOSBdRrJkm8THqjsA</id>
    <link href="https://mp.weixin.qq.com/s/Wy5KPYOSBdRrJkm8THqjsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国专利无效上诉判决，及法律和事实两类问题的区别</title>
    <updated>2020-12-07T07:41:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/zJz_XSK9mUzQ-8RVhgLBnA</id>
    <link href="https://mp.weixin.qq.com/s/zJz_XSK9mUzQ-8RVhgLBnA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国上诉判决：注射剂仿制药侵权，老产品新专利的价值</title>
    <updated>2020-11-30T03:56:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/qFUw8nt78VcfTb_r2c0R9g</id>
    <link href="https://mp.weixin.qq.com/s/qFUw8nt78VcfTb_r2c0R9g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美国上诉判决：药品专利侵权如何算出近亿美元的赔偿额？</title>
    <updated>2020-11-23T09:22:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/fwOKcwiUiaaoUjZace-aNg</id>
    <link href="https://mp.weixin.qq.com/s/fwOKcwiUiaaoUjZace-aNg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PTAB首次因已进行的ANDA诉讼拒绝受理IPR复审</title>
    <updated>2020-11-16T03:16:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/klS_yD7NwIc5047vxh-Eww</id>
    <link href="https://mp.weixin.qq.com/s/klS_yD7NwIc5047vxh-Eww" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>